Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma
Metrics: PDF 1283 views | HTML 1360 views | ?
Ahmed Omar Kaseb1, Manal Hassan1, Sahin Lacin1,3,*, Reham Abdel-Wahab1,4,*, Hesham M. Amin2, Ahmed Shalaby1, Robert A. Wolff1, James Yao1, Asif Rashid2, Bharathi Vennapusa5, Janine Feng5, Toshihiko Ohtomo6
1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
2Division of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
3Department of Medical Oncology, Hacettepe University, Medical Faculty, Ankara, Turkey
4Department of Clinical Oncology, Assiut University Hospital, Assiut, Egypt
5Ventana Medical Systems, Inc., Tucson, Arizona, USA
6Chugai Pharmaceutical Co., LTD., Tokyo, Japan
*These authors contributed equally to this work
Ahmed Omar Kaseb, email: firstname.lastname@example.org
Keywords: hepatocellular carcinoma, glypican-3, immunohistochemistry
Received: June 16, 2016 Accepted: September 05, 2016 Published: September 16, 2016
Hepatocellular carcinoma (HCC) is one of the most deadly cancers worldwide. In patients with HCC, histopathogical differentiation is an important indicator of prognosis; however, because determination of HCC differentiation is difficult, the recently described immunohistochemical (IHC) marker glypican3 (GPC3) might assist in HCC prognostication.The goal of our study was to investigate GPC3’s IHC staining pattern and define the relationship between its expression and patients’ clinicopathologic features and overall survival. We retrieved clinical parameters from 101 pathologically diagnosed HCC patients’ medical records and classified these patients into 4 clinical score categories (0–3) based on increasing GPC3 staining intensity and the percentage of stained tumor cells in their resection and biopsy specimens. Histopathological samples were well, moderately, and poorly differentiated in 33, 22, and 12 patients, respectively, and the GPC3 expression rate was 63%, 86%, and 92%,respectively. The median overall survival was 49.9 months (confidence interval (CI): 35.3–64.6 months) for clinical scores 0–1 and 30.7 months (CI: 19.4–41.9 months) for clinical scores 2–3. This difference was not statistically significant (P = .06) but showed a strong trend. In conclusion, a greater GPC3 expression is associated with a worse HCC prognosis and may be a promising prognostic marker.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.